pSivida (NSDQ:PSDV) and Nicox (EPA:COX) said today that the companies are collaborating to develop a sustained-release drug to lower intraocular pressure in people with glaucoma or ocular hypertension. The deal combines pSivida’s bioerodible sustained-release drug delivery system with Nicox’s nitric oxide-donating compounds. According to the agreement, pSivida is responsible for initial development activities. Nicox is slated […]
